Published in Drug Law Weekly, November 28th, 2006
Tercica licensed from Ipsen the rights to develop and market Somatuline Autogel in the United States and Canada in a transaction that closed on October 13, 2006. The FDA will determine within 60 days whether the submission will be accepted for filing.
As of December 31, 2005, Somatuline and Somatuline Autogel had marketing authorizations in over 50 countries for the treatment of acromegaly and neuroendocrine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.